Answers are grounded in this paper and cite their sources.
Observational study evaluates pan-immune inflammation value as a predictor of neoadjuvant therapy response in locally advanced rectal cancer, highlighting its clinical implications.
Neoadjuvant treatment in locally advanced rectal cancer (LARC) led to downstaging in nearly 50 to 60% of patients and pathological complete response (pCR) rates in 9 to 30% cases. However, cases not responding to neoadjuvant treatment encounter either a delay in definitive treatment or progression. To evaluate the role of pan-immune inflammation value (PIV) as a predictive marker of response to neoadjuvant therapy in LARC. A prospective observational study was conducted to validate the predictive value of response to pretreatment PIV in patients with LARC. One hundred twenty patients were enrolled in the study. Patients with higher PIV values were found to have poorer radiological response as compared with patients with lower values (55.1 vs. 75.8%, p = 0.045). Also, patients with high micro-satellite instability status had poor responses. pCR was seen in 21 patients (19.6%). Patients with high PIV value had a pCR rate of 11.6% as compared with 34.0% in the low PIV group. Pretreatment PIV value appears to be a predictive marker of response to neoadjuvant treatment in LARC.
No takes yet. Share an insight, caveat, or question.
Nagendrappa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: